Who is sponsoring NCT04015596?

NCT04015596 is sponsored by Massachusetts General Hospital.

What condition does NCT04015596 study?

NCT04015596 studies PANDAS, Anxiety Disorder, Autoimmune Diseases, Obsessive-Compulsive Disorder.

What drugs are being tested in NCT04015596?

Interventions: Naproxen Sodium, Placebo.

What is the status of NCT04015596?

NCT04015596 is currently TERMINATED.

Last reviewed 2025-09-25 · How we verify

Trial of Naproxen Sodium for the Treatment of OCD in Children With PANDAS

NCT04015596 PHASE4 TERMINATED

This project aims to rigorously evaluate a potential treatment for inflammation-related Obsessive-Compulsive Disorder (OCD) symptoms in children. To accomplish this goal, the investigators will conduct a double-blind, randomized, placebo-controlled trial of Naproxen Sodium, a nonsteroidal anti-inflammatory drug (NSAID) in participants diagnosed with Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). This research fills a gap in the empirical evidence base for the treatment of PANDAS, and will add to a growing literature of empirically-derived practices for PANDAS.

Details

Lead sponsor	Massachusetts General Hospital
Phase	PHASE4
Status	TERMINATED
Enrolment	5
Start date	Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Apr 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

PANDAS
Anxiety Disorder
Autoimmune Diseases
Obsessive-Compulsive Disorder

Interventions

Naproxen Sodium
Placebo

Countries

United States